Edgar Filing: UNITED THERAPEUTICS Corp - Form 4

UNITED TH Form 4	IERAPEUTICS	Corp									
Form 4 February 03, FORN Check th if no long subject to Section 1 Form 4 o Form 5 obligatio may cont <i>See</i> Instru 1(b).	14 UNITED is box ger 6. r 5 6. r 5 5 5 5 5 5 5 5 5 5 5 5 5	MENT O ursuant to a 7(a) of the	Was F CHAN Section 14 Public Ut	Shington, GES IN I SECUR 6(a) of the	D.C. 20 BENEFI ITIES e Securit ling Com	549 [CIA ies E ipany	L OW xchange Act of	COMMISSION NERSHIP OF e Act of 1934, 1935 or Section 0	OMB Number: Expires: Estimated a burden hou response		
(Print or Type I	Responses)										
MAHON PAUL A Symb UNI			Symbol	NITED THERAPEUTICS Corp				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
	(First) ED THERAPEU TION, 1040 SP		3. Date of (Month/D 02/02/20	-	ansaction			Director X Officer (give below) EVP &		Owner er (specify sel	
SII VER SP	(Street) PRING, MD 209	010	4. If Amendment, Date Original Filed(Month/Day/Year)					 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 			
(City)	(State)	(Zip)				9	•.•	Person			
1.Title of Security (Instr. 3)	2. Transaction Da (Month/Day/Year	tte 2A. Deen r) Executio any		3. Transactio Code (Instr. 8)	4. Securi	ties A spose	cquired d of (D)	uired, Disposed of 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect	
Common Stock	02/02/2017			Code V $M^{(1)}$	Amount 6,000	(D) A	Price \$ 51.37	41,221	D		
Common Stock	02/02/2017			D <u>(1)</u>	6,000	D	\$ 165.1	35,221	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not (9-02) required to respond unless the form displays a currently valid OMB control number.

Edgar Filing: UNITED THERAPEUTICS Corp - Form 4

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number iomof Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of 8 Underlying Securities (Instr. 3 and 4) 5	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Tracking Award	\$ 51.37	02/02/2017		M <u>(1)</u>		6,000	09/15/2011	09/15/2020	Common Stock	6,000

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
MAHON PAUL A C/O UNITED THERAPEUTICS CORPORATION 1040 SPRING STREET SILVER SPRING, MD 20910	1		EVP & General Counsel				
Signatures							
/s/ John S. Hess, Jr. under Power of Attorney	02/03/2017	7					
**Signature of Reporting Person	Date						
Evaluation of Decreases							

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) This exercise of share tracking awards was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.